Assessment of a pharmaceutical interventional programme in patients on medications with renal risk

Arroyo, L. Álvarez; Grana, Eduardo Climent; Ros, N. Bosacoma; Meroño, Susana Roca; Gil, M. Perdiguero; Baines, Juan Pablo Ordovás; Payá, José Sánchez

doi:10.1016/s2173-5085(09)70080-2

Cited by 2 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pharmacists' interventions resulted in decreased contraindications to drugs prescribed based on renal function (from 53.0% to 27.5%), reduced excess polypharmacy, and decreased preventable events from 14 to 5. In addition, pharmacist intervention saved approximately US $2,250 [ 59 , 64 , 65 ].…”

Section: Reviewmentioning

confidence: 99%

Renally Inappropriate Medications in the Old Population: Prevalence, Risk Factors, Adverse Outcomes, and Potential Interventions

AlQashqri

2023

Cureus

View full text Add to dashboard Cite

Like most organs, the renal system decreases in function as we age. In the elderly, chronic kidney disease is common. When patients with chronic kidney disease take nephrotoxic medications, they are more likely to suffer adverse drug reactions, be hospitalized, and spend an extended period in the hospital. Calculating the renal clearance of a drug dose based on its glomerular filtration rate, or creatinine clearance, is necessary. Multiple tools are available for identifying renally inappropriate medications (RIMs). RIM prescriptions can be influenced by various factors, which vary according to the study. A higher number of medications means a higher likelihood of using RIMs. Numerous studies have investigated RIMs. The most contraindicated drug in renal insufficiency patients was a non-steroidal anti-inflammatory medication. A variety of interventions have been used to reduce RIM prescriptions to varying degrees of success.

show abstract

Section: Reviewmentioning

confidence: 99%

Renally Inappropriate Medications in the Old Population: Prevalence, Risk Factors, Adverse Outcomes, and Potential Interventions

AlQashqri

2023

Cureus

View full text Add to dashboard Cite

show abstract

Effectiveness of pharmaceutical care for drug treatment adherence in patients with systemic lupus erythematosus in Rio de Janeiro, Brazil: study protocol for a randomized controlled trial

Oliveira-Santos

Verani

Camacho

et al. 2016

Trials

View full text Add to dashboard Cite

BackgroundTreatment adherence is a primary determinant of the success and effectiveness of healthcare. Lack of adherence can lead to treatment failure and death. Although studies have shown that pharmaceutical intervention can improve drug treatment for patients with chronic diseases, studies on pharmaceutical care are not only inconsistent, they are scarce and limited to developed countries, include few patients, and are not studied in randomized clinical trials. Systemic lupus erythematosus is an autoimmune disease with high hospitalization and case-fatality rates. The adherence rate is low (31.7 %) in this group of patients in Brazil, and drug treatment for the disease is complex. Our objective is to evaluate the effectiveness of pharmaceutical care in drug treatment adherence in patients with systemic lupus erythematosus treated at a rheumatology outpatient clinic in Rio de Janeiro, Brazil.MethodsA randomized clinical trial (pragmatic trial) will be conducted. Adult participants (women) from a public hospital in Rio de Janeiro with a diagnosis of systemic lupus erythematosus will be followed for 12 months. A total of 120 patients will be randomized to two groups: intervention (Dader method for pharmaceutical care) and control (health/dietary counseling and risk reduction). The primary outcome will be drug treatment adherence evaluated by the eight-item Morisky Medication Adherence Scale. Secondary outcomes will be clinical improvement and quality of life.DiscussionPatients with systemic lupus erythematosus present with low treatment adherence, thus justifying the mobilization of human resources to optimize their clinical management. Despite the proven effectiveness of pharmaceutical care for various diseases, there are still no studies evaluating its effectiveness in systemic lupus erythematosus. Our hypothesis is that the intervention will also be effective in this patient group.Trial registrationClinicalTrials.gov identifier: NCT02330250.Electronic supplementary materialThe online version of this article (doi:10.1186/s13063-016-1317-1) contains supplementary material, which is available to authorized users.

show abstract

Assessment of a pharmaceutical interventional programme in patients on medications with renal risk

Cited by 2 publications

References 17 publications

Renally Inappropriate Medications in the Old Population: Prevalence, Risk Factors, Adverse Outcomes, and Potential Interventions

Renally Inappropriate Medications in the Old Population: Prevalence, Risk Factors, Adverse Outcomes, and Potential Interventions

Effectiveness of pharmaceutical care for drug treatment adherence in patients with systemic lupus erythematosus in Rio de Janeiro, Brazil: study protocol for a randomized controlled trial

Contact Info

Product

Resources

About